Trial Profile
Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Delolimogene mupadenorepvec (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Lokon Pharma
- 16 Sep 2022 Planned number of patients changed from 43 to 55.
- 16 Sep 2022 Planned End Date changed from 1 Dec 2021 to 1 Oct 2025.
- 16 Sep 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2024.